Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

Status: Recruiting
Location: See all (107) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Males or females aged 18 to 70 years of age.

• Participants who have a diagnosis of SLE confirmed by a rheumatologist.

• ANA-positive per the Central Lab at screening:

• (a) ANA (b) Anti-dsDNA (c) Anti-Smith (anti-Sm)

• Must be on the standard therapy regimen: antimalarials with or without OCSs

• Must have at screening and baseline:

∙ Clinical SLEDAI-2K ≥ 4 points OR

‣ Clinical SLEDAI-2K \< 4 with GC dose ≥ 7.5 mg/day (prednisone equivalent)

• Should have no evidence of current active infection, (e.g., pneumonia, tuberculosis \[TB\]) or previous TB

• Should have no evidence of malignancy; and clinically significant abnormalities (unless due to SLE).

• No medical history or signs or symptoms of active TB prior to or during Screening.

• Body weight ≥ 40.0 kg

⁃ Negative pregnancy test for females during screening

⁃ Normal HPV test result within 2 years prior to Week 0 (Day 1).

⁃ Willing and able to participate in all required study evaluations and procedures including completion of PROs.

⁃ Willing to not use any other forms of experimental treatment during the study.

Locations
United States
Alabama
Research Site
WITHDRAWN
Anniston
Research Site
NOT_YET_RECRUITING
Birmingham
Arizona
Research Site
NOT_YET_RECRUITING
Phoenix
Research Site
NOT_YET_RECRUITING
Tucson
California
Research Site
NOT_YET_RECRUITING
Fontana
Research Site
NOT_YET_RECRUITING
La Jolla
Research Site
RECRUITING
La Palma
Research Site
RECRUITING
Menifee
Research Site
RECRUITING
San Leandro
Research Site
RECRUITING
Temecula
Florida
Research Site
NOT_YET_RECRUITING
Brandon
Research Site
RECRUITING
Miami
Research Site
NOT_YET_RECRUITING
Miami
Research Site
SUSPENDED
Miami
Illinois
Research Site
RECRUITING
Willowbrook
Indiana
Research Site
RECRUITING
New Albany
Louisiana
Research Site
NOT_YET_RECRUITING
Lake Charles
Maryland
Research Site
NOT_YET_RECRUITING
Silver Spring
Missouri
Research Site
NOT_YET_RECRUITING
Kansas City
New Jersey
Research Site
NOT_YET_RECRUITING
West Long Branch
Oklahoma
Research Site
NOT_YET_RECRUITING
Oklahoma City
Research Site
RECRUITING
Oklahoma City
Tennessee
Research Site
NOT_YET_RECRUITING
Memphis
Research Site
RECRUITING
Memphis
Texas
Research Site
NOT_YET_RECRUITING
Austin
Research Site
RECRUITING
Baytown
Research Site
RECRUITING
Colleyville
Research Site
RECRUITING
Edinburg
Research Site
RECRUITING
Houston
Research Site
RECRUITING
Sugar Land
Washington
Research Site
RECRUITING
Spokane
Other Locations
Canada
Research Site
NOT_YET_RECRUITING
Calgary
Research Site
NOT_YET_RECRUITING
Hamilton
Research Site
NOT_YET_RECRUITING
Richmond
Research Site
NOT_YET_RECRUITING
Toronto
Research Site
NOT_YET_RECRUITING
Winnipeg
France
Research Site
NOT_YET_RECRUITING
Clermont-ferrand
Research Site
NOT_YET_RECRUITING
Lyon
Research Site
NOT_YET_RECRUITING
Marseille
Research Site
RECRUITING
Paris
Research Site
NOT_YET_RECRUITING
Paris
Research Site
NOT_YET_RECRUITING
Pessac
Research Site
NOT_YET_RECRUITING
Saint-denis
Research Site
NOT_YET_RECRUITING
Saint-pierre
Research Site
NOT_YET_RECRUITING
Toulon
Research Site
NOT_YET_RECRUITING
Tours
Research Site
NOT_YET_RECRUITING
Vandœuvre-lès-nancy
Germany
Research Site
NOT_YET_RECRUITING
Bad Abbach
Research Site
NOT_YET_RECRUITING
Hamburg
Research Site
NOT_YET_RECRUITING
Mainz
Research Site
NOT_YET_RECRUITING
München
Italy
Research Site
NOT_YET_RECRUITING
Brescia
Research Site
NOT_YET_RECRUITING
Catania
Research Site
NOT_YET_RECRUITING
Ferrara
Research Site
NOT_YET_RECRUITING
Florence
Research Site
SUSPENDED
Milan
Research Site
NOT_YET_RECRUITING
Milan
Research Site
NOT_YET_RECRUITING
Padova
Research Site
NOT_YET_RECRUITING
Pisa
Research Site
SUSPENDED
Roma
Research Site
NOT_YET_RECRUITING
Roma
Research Site
NOT_YET_RECRUITING
Rozzano
Research Site
NOT_YET_RECRUITING
Udine
Mexico
Research Site
NOT_YET_RECRUITING
Culiacán
Research Site
NOT_YET_RECRUITING
Durango
Research Site
NOT_YET_RECRUITING
Guadalajara
Research Site
SUSPENDED
Guadalajara
Research Site
NOT_YET_RECRUITING
Guadalajara
Research Site
NOT_YET_RECRUITING
Mérida
Research Site
NOT_YET_RECRUITING
México
Research Site
NOT_YET_RECRUITING
México
Poland
Research Site
NOT_YET_RECRUITING
Bydgoszcz
Research Site
NOT_YET_RECRUITING
Częstochowa
Research Site
NOT_YET_RECRUITING
Katowice
Research Site
NOT_YET_RECRUITING
Krakow
Research Site
NOT_YET_RECRUITING
Lodz
Research Site
RECRUITING
Lublin
Research Site
RECRUITING
Nadarzyn
Research Site
NOT_YET_RECRUITING
Nowa Sól
Research Site
NOT_YET_RECRUITING
Poznan
Research Site
NOT_YET_RECRUITING
Poznan
Research Site
NOT_YET_RECRUITING
Poznan
Research Site
RECRUITING
Warsaw
Research Site
NOT_YET_RECRUITING
Warsaw
Research Site
NOT_YET_RECRUITING
Warsaw
Research Site
NOT_YET_RECRUITING
Wroclaw
Spain
Research Site
NOT_YET_RECRUITING
Barcelona
Research Site
NOT_YET_RECRUITING
Barcelona
Research Site
SUSPENDED
Córdoba
Research Site
NOT_YET_RECRUITING
Galdakao
Research Site
NOT_YET_RECRUITING
Madrid
Research Site
NOT_YET_RECRUITING
Madrid
Research Site
NOT_YET_RECRUITING
Madrid
Research Site
NOT_YET_RECRUITING
Sabadell
Research Site
NOT_YET_RECRUITING
Santander
Research Site
NOT_YET_RECRUITING
Seville
Research Site
NOT_YET_RECRUITING
Valencia
Taiwan
Research Site
NOT_YET_RECRUITING
Kaohsiung City
Research Site
NOT_YET_RECRUITING
Kaohsiung City
Research Site
NOT_YET_RECRUITING
New Taipei City
Research Site
NOT_YET_RECRUITING
Taichung
Research Site
NOT_YET_RECRUITING
Taichung
Research Site
NOT_YET_RECRUITING
Tainan
Research Site
NOT_YET_RECRUITING
Tainan County
Research Site
NOT_YET_RECRUITING
Taipei
Research Site
NOT_YET_RECRUITING
Taoyuan
Research Site
NOT_YET_RECRUITING
Zhubei
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2026-04-13
Estimated Completion Date: 2029-01-26
Participants
Target number of participants: 245
Treatments
Other: Anifrolumab
Participants will receive dose A of anifrolumab on X dosing schedule beginning on Day 1 for a maximum of 52 -week during the study
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca
Collaborators: ICON plc

This content was sourced from clinicaltrials.gov

Similar Clinical Trials